Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW 91600.0
(-0.76%)
KRW 91600.0
(-0.76%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 586.79 Billion KRW | 16.52% |
| 2022 | 503.59 Billion KRW | 4.72% |
| 2021 | 480.89 Billion KRW | 21.82% |
| 2020 | 394.74 Billion KRW | 20.94% |
| 2019 | 326.39 Billion KRW | 16.32% |
| 2018 | 280.59 Billion KRW | 2.44% |
| 2017 | 273.91 Billion KRW | -4.71% |
| 2016 | 287.44 Billion KRW | 9.83% |
| 2015 | 261.72 Billion KRW | 8.01% |
| 2014 | 242.3 Billion KRW | 8.26% |
| 2013 | 223.82 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 593 Billion KRW | 0.79% |
| 2024 Q1 | 588.33 Billion KRW | 0.26% |
| 2023 Q2 | 499.74 Billion KRW | -5.33% |
| 2023 Q1 | 527.86 Billion KRW | 4.82% |
| 2023 FY | 586.79 Billion KRW | 16.52% |
| 2023 Q4 | 586.79 Billion KRW | 8.82% |
| 2023 Q3 | 539.24 Billion KRW | 7.9% |
| 2022 Q3 | 498.98 Billion KRW | -2.9% |
| 2022 Q2 | 513.87 Billion KRW | 2.18% |
| 2022 FY | 503.59 Billion KRW | 4.72% |
| 2022 Q1 | 502.93 Billion KRW | 4.58% |
| 2022 Q4 | 503.59 Billion KRW | 0.92% |
| 2021 Q1 | 392.45 Billion KRW | -0.58% |
| 2021 Q4 | 480.89 Billion KRW | -6.28% |
| 2021 FY | 480.89 Billion KRW | 21.82% |
| 2021 Q3 | 513.09 Billion KRW | 34.98% |
| 2021 Q2 | 380.13 Billion KRW | -3.14% |
| 2020 Q2 | 378.45 Billion KRW | 8.63% |
| 2020 Q3 | 419.47 Billion KRW | 10.84% |
| 2020 FY | 394.74 Billion KRW | 20.94% |
| 2020 Q1 | 348.37 Billion KRW | 6.73% |
| 2020 Q4 | 394.74 Billion KRW | -5.9% |
| 2019 FY | 326.39 Billion KRW | 16.32% |
| 2019 Q1 | 289.71 Billion KRW | 3.25% |
| 2019 Q4 | 326.39 Billion KRW | 4.51% |
| 2019 Q3 | 312.31 Billion KRW | 2.85% |
| 2019 Q2 | 303.67 Billion KRW | 4.82% |
| 2018 Q2 | 281.34 Billion KRW | -2.42% |
| 2018 FY | 280.59 Billion KRW | 2.44% |
| 2018 Q4 | 280.59 Billion KRW | 5.83% |
| 2018 Q3 | 265.14 Billion KRW | -5.76% |
| 2018 Q1 | 288.31 Billion KRW | 5.26% |
| 2017 FY | 273.91 Billion KRW | -4.71% |
| 2017 Q4 | 273.91 Billion KRW | 0.0% |
| 2016 Q2 | 295.18 Billion KRW | 4.43% |
| 2016 Q1 | 282.66 Billion KRW | 8.0% |
| 2016 FY | 287.44 Billion KRW | 9.83% |
| 2016 Q3 | 291.72 Billion KRW | -1.17% |
| 2015 Q2 | 278.64 Billion KRW | 4.28% |
| 2015 Q4 | 261.72 Billion KRW | -4.84% |
| 2015 Q1 | 267.2 Billion KRW | 10.28% |
| 2015 Q3 | 275.03 Billion KRW | -1.3% |
| 2015 FY | 261.72 Billion KRW | 8.01% |
| 2014 Q2 | 236.43 Billion KRW | -6.93% |
| 2014 Q1 | 254.04 Billion KRW | 0.0% |
| 2014 Q3 | 239.9 Billion KRW | 1.47% |
| 2014 FY | 242.3 Billion KRW | 8.26% |
| 2014 Q4 | 242.3 Billion KRW | 1.0% |
| 2013 FY | 223.82 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -653.672% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 36.89% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 17.014% |
| HANDOK Inc. | 449.7 Billion KRW | -30.484% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -584.943% |
| Yuhan Corporation | 712.33 Billion KRW | 17.624% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 7.14% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -3591.804% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 31.113% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -996.223% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -185.024% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -680.612% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -297.034% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -733.498% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -653.672% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -1510.466% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -133.642% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -165.872% |
| JW Holdings Corporation | 827.51 Billion KRW | 29.089% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | -34.279% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -54.583% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -639.952% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -738.664% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -141.625% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -77.658% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -653.672% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | -19.749% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 31.612% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -54.583% |
| Yuhan Corporation | 712.33 Billion KRW | 17.624% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | -22.809% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -328.415% |
| Suheung Co., Ltd. | 516.66 Billion KRW | -13.572% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -54.583% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -279.712% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -552.244% |
| CKD Bio Corp. | 170.76 Billion KRW | -243.635% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -140.752% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -272.196% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -1264.028% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -639.952% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 7.229% |
| Boryung Corporation | 373.1 Billion KRW | -57.271% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -181.845% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -185.024% |
| JW Lifescience Corporation | 96.44 Billion KRW | -508.434% |